Abstract S209 (the abstract was presented at ASCO 2022). PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE- RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA
Dr Michael L. Wang, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Recorded @ Vienna Messe Center, June 11, 2022